PRESS RELEASE published on 06/27/2024 at 07:00, 1 year 7 months ago SCHOTT Pharma continues growth path in the second quarter of fiscal year 2024 SCHOTT Pharma reports 11% revenue growth in Q2 2024, reaffirms guidance for fiscal year. Focus on high-value solutions and expansion. Key figures and strategic developments outlined Financial Results Expansion Revenue Growth SCHOTT Pharma High-value Solutions
BRIEF published on 06/14/2024 at 13:03, 1 year 7 months ago SCHOTT Pharma Opens State-of-the-Art Production Facility in Hungary SCHOTT Pharma Pharmaceutical Trends Hungary Production Facility Glass Syringes
BRIEF published on 06/14/2024 at 13:03, 1 year 7 months ago SCHOTT Pharma ouvre une usine de production de pointe en Hongrie SCHOTT Pharma Usine Hongrie Seringues En Verre Tendances Pharmaceutiques
PRESS RELEASE published on 06/14/2024 at 12:58, 1 year 7 months ago Expanding prefillable glass syringe output: SCHOTT Pharma opens state-of-the-art production facility in Lukácsháza, Hungary SCHOTT Pharma opens new production facility in Hungary, expanding prefillable glass syringe output to support pharma market growth and trends SCHOTT Pharma Pharma Industry Hungary Production Facility Prefillable Glass Syringes
BRIEF published on 05/14/2024 at 18:24, 1 year 8 months ago SCHOTT Pharma Reaffirms FY 24 Outlook, Anticipates Slower Growth in FY 25 Due to Reduced Syringe Demand Financial Results SCHOTT Pharma FY 24 Forecast FY 25 Growth Impact Syringe Demand Decrease
BRIEF published on 05/14/2024 at 18:24, 1 year 8 months ago SCHOTT Pharma réaffirme ses perspectives pour l’exercice 24 et prévoit un ralentissement de la croissance au cours de l’exercice 25 en raison de la réduction de la demande de seringues Résultats Financiers SCHOTT Pharma Prévisions Pour L'exercice 24 Impact Sur La Croissance Pour L’exercice 25 Diminution De La Demande En Seringues
PRESS RELEASE published on 05/14/2024 at 18:19, 1 year 8 months ago SCHOTT Pharma confirms outlook for FY 24 based on Q2 results; FY 25 impacted by slower growth from syringes SCHOTT Pharma confirms FY 24 outlook based on Q2 results; FY 25 impacted by slower growth from syringes. H1 24 revenues up 9% at constant currencies Revenue Growth SCHOTT Pharma Syringes FY 24 FY 25
BRIEF published on 05/14/2024 at 18:08, 1 year 8 months ago SCHOTT Pharma Anticipates Fiscal Year 2025 Impact Due to Slower Syringe Sales Revenue Growth EBITDA Margin SCHOTT Pharma Fiscal Year 2025 Syringe Demand
BRIEF published on 05/14/2024 at 18:08, 1 year 8 months ago SCHOTT Pharma anticipe l’impact du ralentissement des ventes de seringues sur l’exercice 2025 SCHOTT Pharma Marge D'EBITDA Hausse Des Revenus Exercice 2025 Demande De Seringues
PRESS RELEASE published on 05/14/2024 at 18:03, 1 year 8 months ago EQS-Adhoc: SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma see FY 25 impacted by slower growth from syringes SCHOTT Pharma AG & Co. KGaA expects slower revenue growth in FY 2024/2025 due to decreased demand for syringes from a major customer, impacting EBITDA margin expansion Revenue Growth EBITDA Margin SCHOTT Pharma AG & Co. KGaA FY 2024/2025 Syringes
Published on 02/11/2026 at 14:35, 1 hour 1 minute ago Worksport Delivers Breakout Q4: Revenue Up 65% YoY, Gross Profit Up 380%
Published on 02/11/2026 at 14:30, 1 hour 6 minutes ago Sekur Private Data CEO Updates on Growth, Market Expansion, Corporate Developments and New Product Launch
Published on 02/11/2026 at 14:00, 1 hour 36 minutes ago Organto Foods Inc. Expands Scalable and Flexible Logistics Platform to Support 2026 Growth
Published on 02/11/2026 at 14:00, 1 hour 36 minutes ago PPX Mining Provides Operational and Corporate Update
Published on 02/11/2026 at 14:00, 1 hour 36 minutes ago Meta Critical Minerals Engages Quad Consulting Group to Advance Table Mountain Silica Project Development Strategy
Published on 02/11/2026 at 15:03, 32 minutes ago Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc
Published on 02/11/2026 at 14:59, 36 minutes ago Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Published on 02/11/2026 at 11:25, 4 hours 10 minutes ago Innelec : Mise à disposition du rapport financier semestriel 2025-26
Published on 02/11/2026 at 08:00, 7 hours 36 minutes ago Imerys-press-release French State acquisition stake Emili Lithium
Published on 02/11/2026 at 08:00, 7 hours 36 minutes ago Imerys-communique-de-presse prise participation Etat Français Projet lithium Emili
Published on 02/10/2026 at 18:24, 21 hours 11 minutes ago Mersen: Number of shares and voting rights as of January 31, 2026
Published on 02/10/2026 at 18:24, 21 hours 11 minutes ago Mersen : nombre d'actions et de droits de vote au 31 janvier 2026
